Tags

Type your tag names separated by a space and hit enter

CRISPR in personalized medicine: Industry perspectives in gene editing.
Semin Perinatol. 2018 Dec; 42(8):501-507.SP

Abstract

While research in gene editing technology has been active since the 1990s, recent advances in CRISPR ease of use have sparked significant enthusiasm in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing has the potential to shape the therapeutic landscape of genetically-defined diseases, with key players such as CRISPR Therapeutics, Intellia, and Editas leading the way in β-thalassemia and sickle cell disease. In coming years, clinical development of CRISPR technology promises to change how we think about monogenic and polygenic diseases, though data is still in its infancy. While concerns regarding safety and administration of CRISPR persist and researchers are still seeking to better understand its effect on the body's ability to recognize and repair damaged DNA, the applications for personalized medicine are exciting and wide-ranging. This review examines potential applications of CRISPR for human therapeutics, with a private sector focus detailing anticipated clinical advances and evolving challenges along the way.

Authors+Show Affiliations

Axiom Life Science, 17 Hulfish St. Suite 240, Princeton, NJ 08540, U.S.A.. Electronic address: Andrew.hong@axiomlifescience.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30376985

Citation

Hong, Andrew. "CRISPR in Personalized Medicine: Industry Perspectives in Gene Editing." Seminars in Perinatology, vol. 42, no. 8, 2018, pp. 501-507.
Hong A. CRISPR in personalized medicine: Industry perspectives in gene editing. Semin Perinatol. 2018;42(8):501-507.
Hong, A. (2018). CRISPR in personalized medicine: Industry perspectives in gene editing. Seminars in Perinatology, 42(8), 501-507. https://doi.org/10.1053/j.semperi.2018.09.008
Hong A. CRISPR in Personalized Medicine: Industry Perspectives in Gene Editing. Semin Perinatol. 2018;42(8):501-507. PubMed PMID: 30376985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CRISPR in personalized medicine: Industry perspectives in gene editing. A1 - Hong,Andrew, Y1 - 2018/10/02/ PY - 2018/11/1/pubmed PY - 2019/9/24/medline PY - 2018/11/1/entrez KW - CRISPR gene editing SP - 501 EP - 507 JF - Seminars in perinatology JO - Semin. Perinatol. VL - 42 IS - 8 N2 - While research in gene editing technology has been active since the 1990s, recent advances in CRISPR ease of use have sparked significant enthusiasm in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing has the potential to shape the therapeutic landscape of genetically-defined diseases, with key players such as CRISPR Therapeutics, Intellia, and Editas leading the way in β-thalassemia and sickle cell disease. In coming years, clinical development of CRISPR technology promises to change how we think about monogenic and polygenic diseases, though data is still in its infancy. While concerns regarding safety and administration of CRISPR persist and researchers are still seeking to better understand its effect on the body's ability to recognize and repair damaged DNA, the applications for personalized medicine are exciting and wide-ranging. This review examines potential applications of CRISPR for human therapeutics, with a private sector focus detailing anticipated clinical advances and evolving challenges along the way. SN - 1558-075X UR - https://www.unboundmedicine.com/medline/citation/30376985/CRISPR_in_personalized_medicine:_Industry_perspectives_in_gene_editing_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0146-0005(18)30086-7 DB - PRIME DP - Unbound Medicine ER -